Evogene CFO discloses initial equity holdings

Evogene Ltd. filed a Form 3 detailing the equity holdings of its Chief Financial Officer, Eldad Yaron.

Rhea-AI Filing Summary

Evogene Ltd. filed a Form 3 detailing the equity holdings of its Chief Financial Officer, Eldad Yaron. He holds 4,100 ordinary shares underlying restricted share units that began vesting on April 1, 2023 at 6.25% per quarter over four years.

He also holds stock options over 15,000 ordinary shares at an exercise price of 12.584 per share, vesting from March 30, 2022 with 25% after one year and 6.25% per quarter thereafter until fully vested on the four-year anniversary. Additional options cover 60,000 ordinary shares at an exercise price of 2.300 per share, vesting 6.25% per quarter over four years from November 20, 2024.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider ELDAD YARON

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Ordinary shares	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 75,000 contracts (Direct); Ordinary shares — 4,100 shares (Direct)

Footnotes (3)

1. F1. The ordinary shares reported in this row consist of 4,100 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person and that commenced vesting on April 1, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.
2. F2. The options reported in this row vest and become exercisable over a period of four years from the March 30, 2022 vesting commencement date: 25% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date.
3. F3. The options reported in this row vest and become exercisable over a period of four years from the November 20, 2024 vesting commencement date, on an equal, quarterly basis (6.25% per quarter), such that they will be fully vested on the four-year anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Evogene (EVGN) disclose in this Form 3 for its CFO?

Evogene’s Form 3 shows CFO Eldad Yaron’s initial equity holdings, including restricted share units and stock options. It outlines how many shares each award covers and the detailed vesting schedules over four-year periods.

How many Evogene (EVGN) ordinary shares are tied to the CFO’s RSUs?

The CFO holds RSUs over 4,100 Evogene ordinary shares. These units began vesting on April 1, 2023, with 6.25% of the grant vesting each quarter so that the award becomes fully vested after four years.

What stock options does Evogene (EVGN) CFO Eldad Yaron hold?

He holds options over 15,000 ordinary shares with an exercise price of 12.584 per share and options over 60,000 ordinary shares at 2.300 per share, each with separate four-year vesting schedules and defined vesting commencement dates.

How do the 15,000-share Evogene (EVGN) options vest for the CFO?

The 15,000-share option grant vests over four years from a March 30, 2022 commencement date. Twenty‑five percent vested on the one‑year anniversary, and the remaining options vest at 6.25% per quarter across the following twelve quarters.

What is the vesting schedule for the 60,000 Evogene (EVGN) options?

The 60,000-share option grant vests over four years from a November 20, 2024 commencement date. It vests on an equal quarterly basis at 6.25% per quarter, becoming fully vested on the four‑year anniversary of the grant date.

Does the Evogene (EVGN) Form 3 show any recent insider buying or selling?

The Form 3 lists holdings, not recent trades, for CFO Eldad Yaron. It details his existing RSUs and stock options with exercise prices, vesting schedules, and expiration dates, but does not report open‑market purchases or sales of Evogene shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 08:09 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ELDAD YARON

(Last) (First) (Middle)

30 HAIRIT ST.

(Street)

MAALE ADUMIM 9853815

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares(1)	4,100	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	(2)	03/30/2032	Ordinary shares	15,000	$12.584	D
Stock Option (right to buy ordinary shares)	(3)	11/20/2034	Ordinary shares	60,000	$2.3	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of 4,100 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person and that commenced vesting on April 1, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.

2. The options reported in this row vest and become exercisable over a period of four years from the March 30, 2022 vesting commencement date: 25% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date.

3. The options reported in this row vest and become exercisable over a period of four years from the November 20, 2024 vesting commencement date, on an equal, quarterly basis (6.25% per quarter), such that they will be fully vested on the four-year anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)